Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Retained Earnings (2016 - 2025)

Alterity Therapeutics has reported Retained Earnings over the past 5 years, most recently at -$98.9 million for Q2 2019.

  • For Q2 2019, Retained Earnings fell 0.85% year-over-year to -$98.9 million; the TTM value through Jun 2019 reached -$98.9 million, down 0.85%, while the annual FY2019 figure was -$98.9 million, 0.85% down from the prior year.
  • Retained Earnings for Q2 2019 was -$98.9 million at Alterity Therapeutics, down from -$96.3 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $93.2 million in Q2 2016 and troughed at -$98.9 million in Q2 2019.
  • A 5-year average of -$73.7 million and a median of -$96.3 million in 2018 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: surged 202.39% in 2016 and later tumbled 198.81% in 2017.
  • Year by year, Retained Earnings stood at -$86.4 million in 2015, then decreased by 11.64% to -$96.4 million in 2016, then dropped by 0.71% to -$97.1 million in 2017, then grew by 0.78% to -$96.3 million in 2018, then fell by 2.68% to -$98.9 million in 2019.
  • Business Quant data shows Retained Earnings for ATHE at -$98.9 million in Q2 2019, -$96.3 million in Q4 2018, and -$98.1 million in Q2 2018.